These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27053057)

  • 41. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
    Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
    Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.
    Hashimoto M; Sugidachi A; Isobe T; Niitsu Y; Ogawa T; Jakubowski JA; Asai F
    Biochem Pharmacol; 2007 Oct; 74(7):1003-9. PubMed ID: 17681285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
    Judge HM; Buckland RJ; Jakubowski JA; Storey RF
    Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
    Singh S; Singh M; Grewal N; Khosla S
    Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
    Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia.
    Nagahama R; Matoba T; Nakano K; Kim-Mitsuyama S; Sunagawa K; Egashira K
    Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2427-34. PubMed ID: 22879581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platelet inhibition with prasugrel in patients with acute myocardial infarction undergoing therapeutic hypothermia after cardiopulmonary resuscitation.
    Flierl U; Röntgen P; Zauner F; Tongers J; Berliner D; Bauersachs J; Schäfer A
    Thromb Haemost; 2016 May; 115(5):960-8. PubMed ID: 26790884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
    Liu F; Tantry US; Gurbel PA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1149-65. PubMed ID: 25873127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiangiogenic Effect of Platelet P2Y
    Wang X; Zhao H; Yang N; Jin Y; Chen J
    Biomed Res Int; 2021; 2021():5529431. PubMed ID: 33898623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y
    Rollini F; Franchi F; Singh K; Cho JR; Bhatti M; DeGroat C; Hu J; Aggarwal N; Alobaidi Z; Thano E; Ferrante E; Zenni M; Bass TA; Angiolillo DJ
    Thromb Haemost; 2016 Nov; 116(6):1060-1069. PubMed ID: 27488362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome.
    Tsukiyama Y; Kozuki A; Shinke T; Otake H; Kijima Y; Masano T; Nagoshi R; Shibata H; Takeshige R; Yanaka KI; Shite J; Hirata KI
    J Cardiol; 2018 Nov; 72(5):403-410. PubMed ID: 29731189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
    Asher E; Abu-Much A; Goldenberg I; Segev A; Sabbag A; Mazin I; Shlezinger M; Atar S; Zahger D; Polak A; Beigel R; Matetzky S;
    PLoS One; 2016; 11(6):e0157437. PubMed ID: 27310147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
    Clavijo LC; Al-Asady N; Dhillon A; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):516-520. PubMed ID: 29221961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?
    Vannini L; Muro A; Sanchis J; Ortiz-Pérez JT; Flores Umanzor E; López-Lereu MP; Badimon L; Sabaté M; Brugaletta S
    Int J Cardiol; 2016 Nov; 223():226-227. PubMed ID: 27541661
    [No Abstract]   [Full Text] [Related]  

  • 57. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
    Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
    Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
    Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
    Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
    Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.